Introduction
Prostate adenocarcinoma is now the most common cancer and the second leading cause of cancer mortality in men of the USA. In 1999 there were an expected 184,500 new cases and also 39,200 deaths from this disease. 1 Because prostate cancer shows wide variability in clinical behavior 2 accurate prediction of tumor progression is being pursued vigorously as a clinical research goal. In recent years many laboratories have been performing molecular genetic analysis on prostate tumor tissue, and it has become evident that prostate cancer develops as a result of multiple somatic alterations in critical genes, including both dominant oncogenes and recessive tumor suppressor genes. 3, 4 Identi®cation of these genes will be important for prognosis and treatment in prostate cancer.
Comparative genomic hybridization (CGH) is a technique which measures regional DNA copy number alterations in the entire genome of tumors, such that tissue DNA can be characterized as to the frequency and positioning of altered DNA copy number patterns. There are several published reports on CGH of DNA from paraf®n-embedded tissue sections from prostate tumor. 5 ± 7 However, tumor DNA extracted from whole sections is inevitably contaminated with normal DNA because the malignant epithelial cells are intimately associated with normal stromal cells. Thus, microdissection has been used recently to isolate pure tumor cells for subsequent molecular genetic analysis. 8 In the present study we performed microdissection of prostate cancer cells, and performed DOP-PCR (degenerate oligonucleotide primed PCR) and CGH so as to more clearly de®ne regions of DNA copy number alterations which occur during the development of prostate cancer.
Materials and methods
Primary tumor tissues of 23 cases of prostate adenocarcinoma were obtained from archival tissue banks at UCSF Medical School. The tissues were obtained from prostate surgery, either transurethral resection or radical prostatectomy, performed between 1985 and 1996. The tissues were formalin-®xed and paraf®n-embedded. Gleason grades ranged from 5 to 9.
A 5 m section was cut and stained with hematoxlyin and eosin for the histopathological inspection. An adjacent section was stained with 0.1% methyl green for microdissection. Microdissection was performed using no. 11 scalpel blades under a dissecting microscope. Microdissected tumor cells were collected in 1.5 ml Eppendorf tubes and digested in PCR buffer overnight at 37 C with 0.4 mg/ml proteinase K (Boehringer-Mannheim Corp., Indianapolis, IN). On each of three subsequent days, fresh proteinase K was added at equal concentration for continued digestion. After the third day, any remaining proteinase K was inactivated by incubating for 5 min at 95 C.
DOP-PCR
To perform DOP-PCR 3 ml of the digested cell solution was added to PCR reaction mix to give 50 ml solution with a composition of 200 mM each dNTP, 1. CGH CGH was performed as described previously. 10 PCR ampli®ed tumor DNA was labeled by nick translation with FITC-12-dUTP directly or digoxigenin-11-dUTP (Boehringer Mannheim Corp., Indianapolis, IN) indirectly. PCR ampli®ed normal male DNA was labeled by nick translation with Texas Red-5-dUTP or FITC-12-dUTP (DuPont, Boston, MA). Labeled DNA was ethanol precipitated together with 30 mg of unlabeled Human Cot-1 DNA (Gibco BRL, Grand Island, NY), and subsequently redissolved in 10 ml of hybridization solution (50% formamide, 10% dextran sulfate in 2Â SSC). This DNA was denatured for 8 min at 73 C, and layered onto normal metaphase slides for 3 days' hybridization at 37 C. After hybridization, the slides were washed in blocking solution (4Â SSC, 1% (w/v) BSA) for 5 min and if tumor DNA was labeled with digoxigenin, the slides were then incubated in 1 mg/ml rhodamine-conjugated Fab fragment of sheep anti-digoxigenin (Boehringer Mannheim Corp., Indianapolis, IN) in 4Â SSC, 1% BSA. The slides were then washed in 4Â SSC, 4Â SSC, 0.1% (v/v) Triton X-100, 4Â SSC solution and ®nally distilled water. The slides were air dried and counter stained with DAPI (4 H , 6-diamino-2-phenylindole) in phenylenediamine antifade solution. 11 
Quantitative image analysis
Quantitative image acquisition was carried out using the QUIPS (Quantitative image processing system) as described by Piper et al. 12 Images of four to seven different metaphase spreads were obtained under computer control and analyzed to provide pro®les of normalized ratios of the intensity of green¯uorescence to red uorescence at each data channel along the length of the entire genome. A threshold of 1.15 was set to de®ne signi®cant DNA copy number gain and 0.85 for signi®-cant DNA copy number loss. Chromosome Y and heterochromatic regions such as centromere or paracentromere and near-telomere were excluded from evaluation because those regions show large variations in¯uores-cence ratios due to the localized abundance of repetitive DNA. Also, results on chromosomes 9 and 13 were cautiously inspected before including them in pro®les of genetic variation because normal DNA vs normal DNA hybridization sometimes showed variations ranging outside 0.85 ± 1.15 for these chromosomes.
Results
This study reports the results of CGH analysis from DNA extracted from 23 adenocarcinoma tumors of the prostate gland. In all cases, the tumor specimens were formalin ®xed, and paraf®n embedded and archived by UCSF pathologists. For each specimen microdissection was performed by ®rst removing stromal tissues from around the tumor glands and then scooping tumor glands individually off the microscope slide (Figure 1) .
After DOP-PCR of proteinase K-treated tumor glands, CGH was performed to map DNA copy number alterations throughout the genome. An example of the CGHgenerated¯uorescence pro®les is shown in Figure 2 .
For this particular case, gain in DNA copy number are located at chromosome 4q22 ± q26, chromosome 8q21.1 ± q21.3, chromosome 14q11.1 ± q21, and chromosome X. The regions of DNA copy number loss were at chromosomes 8p, 16p, 16q22-qter, 19q, 20q and 22. Table 1 shows a summary of the CGH results from all 23 cases studied. Figure 3 .
The frequency of each chromosomal change by gain was highest in chromosome 8q (91.3%), followed by chromosome X (43.5%), chromosomes 3, 4, 7 and 20 
Discussion
The detection of gross chromosomal alteration in dimensions such as ampli®cation, deletion or translocation might be the ®rst step in searching for genetic changes of tumor cells. Although conventional cytogenetic Table 1 Pro®le changes of 23 cases of prostate cancers
Cases
Pro®le changes 1 8q21 ± q22( ), 16q22-qter( 7 ), 20( 7 ), Xp21-qter( ) 2 8q21.1 ± q22( ), X( ) 3 8q21( ), X( ) 4 8q21.1 ± q22( ), 18q( 7 ), X( ) 5 8q21( ), 18q21 ± q22( 7 ), Xq( ) 6 8p( 7 ), 8q21.1 ± q21.3( ), 17q12 ± q24( 7 ), 20q12-qter( 7 ), X( ) 7 8q21( ), 14q31-qter( 7 ), 15q22-qter( 7 ), 17q( 7 ), 20q( 7 ), 22q( 7 ), X( ) 8 8q21 ± q23( ), 20q( 7 ) 9 16p( 7 ), 18p( 7 ) 10 4q22 ± q26( ), 8p( 7 ), 8q21 ± q21.3( ), 14q11.1 ± q21( ), 16p( 7 ), 19q( 7 ), 22( 7 ), X( ) 11 6p( ) 12 8q( ) 13 3q( ), 8q21( ), 20q( ), 22( ) 14 8q21( ) 15 4q( ), 8q( 7 ), 8q21( ), 12q23-qter( 7 ), 16p( 7 ), 19q( 7 ), 20( 7 ), 22q( 7 ), Xq11 ± q26( ) 16 2q22 ± q33( ), 7q( ), 8q11 ± q22( ), 12( 7 ), 16p( 7 ), 20( 7 ), 22q( 7 ) 17 7q( ), 8q21( ), 12q21 ± q23( ), 15q21-qter( ), 18q12 ± q22( 7 ), 20( 7 ), 22( 7 ) 18 8q21( ), 11q23-qter( 7 ), 15q( 7 ) 19 8q21( ), 15q( 7 ), 16( 7 ), 18q21 ± q23( 7 ), 21q( 7 ) 20 8q21( ), 10q( 7 ), 14q23-qter( 7 ), 18q( 7 ), 21 1p22 ± p31( 7 ), 3q22 ± q29( ), 4( 7 ), 8q21( ), 14q( 7 ), 18q( 7 ) 22 8q21( ), 15q( 7 ), 18q( 7 ), Xq( ) 23 8q21.1 ± q21.3( ), 20q( ) Genetic alterations in microdissected prostate cancer S-H Kim et al analysis has been widely used for that purpose, it shows severe limitations in detecting genetic changes in that modest-sized alterations are not detectable. In the present environment, CGH is frequently used to replace conventional cytogenetics in that it adds higher resolution. However, one of the limitations of CGH for detecting genetic changes is that normal cell contamination of tumor cell samples can skew results, causing a number of alterations to be missed. 13 Thus, microdissections to provide samples that contain only tumor cells were performed in this study. Another concern with CGH is the fact that particular regions of chromosomes are dif®-cult to interpret for copy number alterations due to large amounts of repetitive DNA near chromosome centromeres and telomeres and the fact that chromosomes 9 and 13 often show variations of CGH pro®les even when normal DNA is hybridized vs normal DNA. To eliminate identifying false positive alterations, we have interpreted alterations in these regions with great caution. With careful tissue microdissection and DOP-PCR ampli®cation of isolated DNA, we found that 100% of our cases showed at least one gain and/or loss of DNA regions. This frequency of alterations is signi®cantly higher than 74%, which previously was reported for primary prostate tumors. 5 This difference might result from a different population being studied, but it is more likely that CGH is much more sensitive using DNA extracted from microdissected tissue resulting in a higher proportion of tumor DNA.
In the present study high copy number gains, which have been detected in other cancers, 14, 15 were seldom detected. In addition, losses were detected at almost the same frequency as the low level gains. The most common regions of loss in this study were on chromosomes 8p, 14, 15q, 16, 18, 20 and 22. Our results are in general agreement with previous studies that measured loss of heterozygosity in primary prostate cancer, and for which the most common sites of loss have been reported on chromosomes 8p, 10q, 16q, and 18q. 6,16 ± 18 Thus it appears that oncogene ampli®cation is not a strong driver for progression, and that inactivation of putative recessive tumor suppressor genes at several chromosomal sites is especially important in prostate cancer development, as suggested by others. 4, 5, 19 Several known candidate tumor suppressor genes map in the regions of loss that were determined in this study. One such candidate is CTFC, a zinc ®nger protein that binds to the promoter for MYC and appears to regulate MYC expression. It maps at the chromosome site 16q22.1. 20 Genetic change of chromosome 8p has been widely studied in prostate cancer, and potential tumor suppressor genes in this region include DNA polymerase beta (POLb), heregulin (HGL), the Werner Syndrome gene (WRN), ®broblast growth factor receptor-1 (FGFR1), protein phosphatase-2 (PPP2CB) and the adrenergic beta-3 receptor (ADRb3). 21 The DCC gene was previously shown to be lost frequently in colon as well as prostate carcinomas, and it maps at chromosome 18q, a region of common loss in our study. 21 Gains were most frequently detected in chromosome X and chromosome 8q. Chromosome X harbors the protooncogenes ELK1 (a member of ets-oncogene family) and RAFA1. 22 Chromosome 8 contains the MYC oncogene at 8q24 and its over-expression is well known in prostate cancer. 23, 24 Ampli®cation was noted near chromosome 8q21 in our study, indicating that this region may harbor tentative oncogene(s) in prostate cancer. The early growth response alpha gene (EGR-a) is located near D8S257 in 8q21 25, 26 and is a candidate oncogene in the region. It encodes zinc ®nger DNA-binding transcription factors. It is expressed in androgen-independent prostate cells such as PC3 and DU145 and regulated by androgen and EGF, which are important for the prostate development and differentiation. Even though the mRNA expression level of this gene appears to be low in prostate cancer tissue sections, 26 this gene should remain as a candidate for further studies.
Finally we should note that the existence of a number of candidate genes as tumor suppressors and oncogenes for prostate cancer does not eliminate the need for more precise localization and identi®cation of other as yet unidenti®ed genes in the regions of DNA copy number loss or gain respectively. It would be extremely bene®cial to extensively perform loss of heterozygosity or quantitative real time PCR analysis on microdissected prostate tumor cells 27 so as to aid in the identi®cation of such genes.
